Important Class Action Settlement Information
In a significant development, a proposed class action settlement has been announced relating to the purchasers of common stock of Applied Therapeutics, Inc. This notice is intended for all individuals or entities that bought stocks of Applied Therapeutics on U.S. exchanges from January 3, 2024, to December 2, 2024. Understanding the implications of this settlement is essential, as it may affect your rights as a stockholder.
Overview of Court Proceedings
The United States District Court for the Southern District of New York has approved this notice regarding the settlement. This is an important opportunity for stockholders to understand their rights and the outcome of the litigation concerning Applied Therapeutics. The case in question is formally titled In re Applied Therapeutics Securities Litigation, with case number 1:24-cv-09715.
Understanding the Settlement
The court hearing is scheduled for March 19, 2026, where various key decisions will be made concerning the settlement. Proposed terms include a settlement amount of $15,000,000 in cash and warrants, which allow for the purchase of 1,000,000 shares of Applied common stock at a cost of $0.48 per share. Stakeholders are encouraged to attend this pivotal meeting.
Claiming Your Share of the Settlement
If you have acquired shares of Applied Therapeutics during the specified period, it is crucial to submit your Proof of Claim and Release, along with the necessary documentation. The deadline for submissions is April 8, 2026, whether electronically or through the mail. Ensuring timely submission is vital to ascertain your eligibility for participating in the settlement fund.
Opting Out and Objecting
Class members have the right to opt-out of the settlement. To do this, a written request must be submitted no later than February 26, 2026. Additionally, anyone wishing to object to the settlement must also submit their written objection by this date. This ensures that all voices are heard during the court's evaluation of the settlement proposal.
Next Steps for Class Members
Class members should remain informed and proactive regarding their options in this settlement. If an individual chooses to remain a part of the class, they will be bound by any judgment and resolution the court may decree. This settlement represents a pivotal moment in the ongoing legal matters surrounding Applied Therapeutics.
Contact Information for Further Inquiries
If you need further details, you may contact the Claims Administrator for information regarding the settlement and the necessary documents to complete your claim. Addressing inquiries promptly is encouraged to ensure transparency and support for shareholders who are affected by this litigation.
Frequently Asked Questions
What is the purpose of this notice?
This notice informs shareholders about a proposed class action settlement related to Applied Therapeutics, providing crucial information on rights and obligations.
What should I do if I purchased shares during the specified period?
If you bought shares between January 3, 2024, and December 2, 2024, you need to submit a Proof of Claim to participate in the settlement fund.
How can I opt-out of the class action?
To opt-out, send a written request to the appropriate parties by February 26, 2026, following the instructions in the Longform Notice.
Can I object to the settlement?
Yes, class members can file objections regarding the settlement, but they must be submitted by the February 26, 2026 deadline.
Who can I contact for more information?
You can reach out to the Claims Administrator or designated Lead Counsel for additional support regarding the settlement and claims processes.
